Logo

Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)

Share this

Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)

Shots:

  • Evotec and GARDP enter into an agreement to develop novel therapies for growing   threat of antimicrobial resistance (AMR)
  •  The focus of the collaboration is to combine GARDP’s clinical expertise with Evotec’s drug discovery platform to develop antibiotics for AMR and establish antibiotic discovery- development platform with portfolio of antibiotic assets
  • Evotec’s anti-infective platform enabling discovery and development of vaccines to treat- prevent serious life-threatening infections arising from Gram-positive and Gram-negative bacteria including MDR organism with a collection of strains producing in-vitro and in-vivo therapies

Ref: Evotec | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions